In this video, Robert Huddart, MBBS, MRCP, FRCR, PhD, of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, evaluates the efficacy of minimally invasive retroperitoneal lymph node dissection (MI-RPLND) in stage IIa seminoma (SEM) patients. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Huddart reports that MI-RPLND used in conjunction with adjuvant carboplatin is a promising treatment option for stage IIa SEM.